INCY
Incyte Corporation
NASDAQ: INCY · HEALTHCARE · BIOTECHNOLOGY
$99.10
+1.39% today
Updated 2026-04-29
Market cap
$19.80B
P/E ratio
14.00
P/S ratio
3.69x
EPS (TTM)
$7.08
Dividend yield
—
52W range
$58 – $112
Volume
1.6M
WallStSmart proprietary scores
83
out of 100
Grade: A
Strong Buy
Investment rating
8.7
Growth
A7.8
Quality
B+9.5
Profitability
A+9.3
Valuation
A+5/9
Piotroski F-Score
Moderate
3.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$108.09
+9.07%
12-Month target
$91.03
-8.14%
Intrinsic (DCF)
$624.90
Margin of safety
+84.18%
2 Strong Buy9 Buy13 Hold1 Sell1 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.07 — safe zone
+ Profit margin 26.70% — above average
+ ROE 30.80% — strong efficiency
+ Free cash flow $521.42M — positive
+ Revenue growth 20.90% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $3.39B | $3.70B | $4.24B | $5.14B | $5.36B | $5.7B |
| Net income | $340.66M | $597.60M | $32.62M | $1.29B | $299.28M | — |
| EPS | — | — | — | — | $7.08 | $7.66 |
| Free cash flow | $892.11M | $449.00M | $249.07M | $1.35B | $521.42M | — |
| Profit margin | 10.04% | 16.17% | 0.77% | 25.03% | 26.70% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-17 | CAGNONI, PABLO J | Sale | 12,590 | — |
| 2026-04-17 | CAGNONI, PABLO J | Sale | 6,077 | — |
| 2026-04-17 | CAGNONI, PABLO J | Sale | 18,667 | $96.50 |
Peer comparison
Smart narrative
Incyte Corporation trades at $99.10. representing a P/E of 14.00x trailing earnings. Our Smart Value Score of 83/100 indicates the stock is excellent. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 3.07, it sits in the safe zone. TTM revenue stands at $5.36B. with profit margins at 26.70%. Our DCF model estimates intrinsic value at $624.90.
Frequently asked questions
What is Incyte Corporation's stock price?
Incyte Corporation (INCY) trades at $99.10.
Is Incyte Corporation overvalued?
Smart Value Score 83/100 (Grade A, Strong Buy). DCF value $624.90.
What is the price target of Incyte Corporation (INCY)?
The analyst target price is $108.09, representing +9.1% upside from the current price of $99.10.
What is the intrinsic value of Incyte Corporation (INCY)?
Based on our DCF model, intrinsic value is $624.90, a +84.2% margin of safety versus $99.10.
What is Incyte Corporation's revenue?
TTM revenue is $5.36B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
3.07 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio3.69x
ROE30.80%
Beta0.86
50D MA$95.98
200D MA$93.22
Shares out0.20B
Float0.17B
Short ratio—
Avg volume1.6M
Performance
1 week+4.70%
1 month+5.09%
3 months-0.97%
YTD+0.33%
1 year—
3 years—
5 years—